NCT07550127 Peri-implantitis Management: Surgical and Maintenance Outcomes
| NCT ID | NCT07550127 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Peri-implantitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2026-02-16 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2026-02-16 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn how two standard surgical treatments for peri-implantitis affect inflammation around dental implants. Participants will be randomly assigned to receive resective surgery with implantoplasty or resective surgery with mechanical debridement only. Participants will provide blood samples before surgery, about 48 hours and 2 weeks after surgery. Participants will also provide a small gum tissue sample and fluid from around the implant at baseline and about 3 months after surgery. Participants will be followed in a maintenance program for up to 5 years.
Eligibility Criteria
Inclusion Criteria To be enrolled the participant must met the following inclusion criteria: 1. Aged 18 or older. 2. In good general health, classified as ASA Physical Status I or II. 3. Diagnosed with peri-implantitis requiring resective surgical treatment, characterized by: Bleeding on probing (BOP) around dental implants. Probing pocket depths (PPD) greater than 6 mm. Implants in function for over 1 year with progressive bone loss exceeding 3 mm. Initial screening confirmed by panoramic radiographs, cone-beam computed tomography (CBCT), and clinical diagnosis. To be enrolled in the maintenance phase, participants must meet clinical stability criteria at the time of enrollment: * Probing depth (PD) ≤ 5 mm * Bleeding on probing (BOP) ≤ 1 point * Absence of suppuration (SOP) * Absence of progressive bone loss compared to pre-treatment bone levels Exclusion Criteria: 1. Patients with autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis) that could alter immune cell profiles independent of local peri-implant inflammation. 2. Chronic use of systemic corticosteroids or immunosuppressants within the past 3 months. 3. Uncontrolled diabetes (HbA1c \> 7.5%) due to its potential impact on healing and immune response. 4. Active infection or antibiotic use in the 30 days prior to baseline sampling. 5. Pregnancy or breastfeeding. 6. Inability to undergo venipuncture or tolerate soft tissue biopsy. 7. Inability to attend the 3-month follow-up visit or comply with study protocol. 8. History of malignancy requiring systemic therapy within the past 5 years.
Contact & Investigator
Andrea Ravida, DDS, MS, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh, Department of Periodontics and Oral Medicine.
Frequently Asked Questions
Who can join the NCT07550127 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peri-implantitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07550127 currently recruiting?
Yes, NCT07550127 is actively recruiting participants. Contact the research team at andrearavida@pitt.edu for enrollment information.
Where is the NCT07550127 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07550127 clinical trial?
NCT07550127 is sponsored by University of Pittsburgh. The principal investigator is Andrea Ravida, DDS, MS, PhD at University of Pittsburgh, Department of Periodontics and Oral Medicine.. The trial plans to enroll 44 participants.